EdiGene, a China gene editing company, announced a research collaboration with the University of Wisconsin–Madison to identify candidates for genetic disease therapies. EdiGene’s US R&D Center will work with the David Gamm Laboratory at UWM to evaluate the pharmacological properties of RNA base editing candidates derived from EdiGene's LEAPER™ RNA platform. The program will focus on in vivo therapies for ophthalmology indications. In September, EdiGene started a China Phase I trial of its gene-editing hematopoietic stem cell therapy to treat transfusion dependent β-thalassemia, a rare genetic disease. More details.... Share this with colleagues: // //